According to the presence of small nodal tumor infiltrates (SNTI) and bone marrow micrometastases (BMM), there were 4 subgroups of patients, including 61 SNTI-negative (SNTI−), BMM-negative (BMM−) patients (reference group); 15 SNTI-positive (SNTI+), BMM− patients (overall survival [OS]: hazard ratio [HR], 1.16; 95% CI, 0.43-3.14; disease-specific survival [DSS]: HR, 1.28; 95% CI, 0.52-3.18); 40 SNTI−, BMM-positive (BMM+) patients (OS: HR, 1.42; 95% CI, 0.73-2.77; DSS: HR, 1.42; 95% CI, 0.74-2.72), and 6 SNTI+, BMM+ patients (OS: HR, 5.96; 95% CI, 1.66-21.49; DSS: HR, 6.73; 95% CI, 2.29-19.76) (likelihood ratio test: OS, P = .03; DSS, P = .006).